The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 72, Issue 7, Pages 2483-2498
Publisher
Springer Science and Business Media LLC
Online
2023-04-06
DOI
10.1007/s00262-023-03441-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
- (2021) Landon C Brown et al. Journal for ImmunoTherapy of Cancer
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
- (2021) Xiaoxiang Zhou et al. LANCET ONCOLOGY
- Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
- (2021) Xiaofei Zhu et al. LANCET ONCOLOGY
- Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
- (2021) Danielle M. Lussier et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation
- (2021) Timothy D. Martin et al. SCIENCE
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
- (2021) Yuanyuan Zhang et al. CANCER CELL
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
- (2021) Xiaona Xie et al. Frontiers in Cell and Developmental Biology
- 12‐Chemokine signature, a predictor of tumor recurrence in colorectal cancer
- (2020) Ryuma Tokunaga et al. INTERNATIONAL JOURNAL OF CANCER
- Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
- (2020) Jing Li et al. JOURNAL OF CLINICAL INVESTIGATION
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- (2020) Bruno Bockorny et al. NATURE MEDICINE
- SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
- (2020) Pengju Li et al. Aging-US
- CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade
- (2020) Guangchuan Wang et al. Cancer Discovery
- Macrophage-based approaches for cancer immunotherapy
- (2020) Nicholas R. Anderson et al. CANCER RESEARCH
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
- (2019) Sarabjot Pabla et al. Journal for ImmunoTherapy of Cancer
- BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
- (2019) Raunak Shrestha et al. Genome Medicine
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
- (2019) Andrea Castro et al. BMC Medical Genomics
- Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
- (2019) Jacqueline V. Aredo et al. LUNG CANCER
- UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
- (2019) Yochai Wolf et al. CELL
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
- (2018) Yang Liu et al. CANCER CELL
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- (2018) Katherine A. Hoadley et al. CELL
- The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
- (2018) Lu Huang et al. CLINICAL CANCER RESEARCH
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- High response rate to PD-1 blockade in desmoplastic melanomas
- (2018) Zeynep Eroglu et al. NATURE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
- (2018) Diana Miao et al. NATURE GENETICS
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
- (2018) Li Wang et al. Nature Communications
- Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer
- (2018) Xiangchun Li et al. JAMA Oncology
- Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
- (2018) Jake R. Conway et al. Genome Medicine
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
- (2016) Nadeem Riaz et al. NATURE GENETICS
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
- (2015) Antonio Colaprico et al. NUCLEIC ACIDS RESEARCH
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- (2012) Jane L. Messina et al. Scientific Reports
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started